Drug targeting in Leishmania donovani infections using tuftsin‐bearing liposomes as drug vehicles

No abstract is available for this paper.

• Publication year

  1989

• Venue

  FEBS Letters

• Publication date

  1989-03-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0014-5793(89)80222-4PMID 2538359
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protection of mice against Plasmodium berghei infection by a tuftsin derivative

  1986cited by this paper
• Liposomes as drug carriers in leishmaniasis and malaria.

  1986cited by this paper
• Transbilayer phosphatidylcholine distributions in small unilamellar sphingomyelin-phosphatidylcholine vesicles: effect of altered polar head group.

  1985cited by this paper
• Liposomes for drugs and vaccines

  1985cited by this paper
• Specific interactions of liposomes with PMN leukocytes upon incorporating tuftsin in their bilayers

  1984cited by this paper
• Drug carriers in biology and medicine

  1979cited by this paper
• CALORIMETRIC METHODS OF ANALYSIS.

  1972cited by this paper

• Aster peduncularis Wall. Ex. Nees: in-vitro antibacterial and antileishmanial activities of essential oil from India

  2025cites this paper
• Development of a new assay for quantification of parasite load of intracellular Leishmania sp. in macrophages using flow cytometry

  2024cites this paper
• Solidago virgaurea L.: Chemical composition, antibacterial, and antileishmanial activity of essential oil from aerial part

  2024cites this paper
• USO DA CITOMETRIA DE FLUXO PARA QUANTIFICAÇÃO DE Leishmania sp. INTRACELULAR

  2022cites this paper
• Functionalized lipid-based drug delivery nanosystems for the treatment of human infectious diseases

  2022cites this paper
• Antileishmanial drug screening

  2021cites this paper
• Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis - A review.

  2021cites this paper
• Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the treatment of infectious diseases and tumors.

  2020cites this paper
• What Drives Innovation: The Canadian Touch on Liposomal Therapeutics

  2019cites this paper
• Innovative Solutions for the Control of Leishmaniases: Nanoscale Drug Delivery Systems.

  2019cites this paper
• Evaluation of antileishmanial potential of computationally screened compounds targeting DEAD-box RNA helicase of Leishmania donovani.

  2019cites this paper
• Liposomal formulations in the pharmacological treatment of leishmaniasis: a review

  2017cites this paper
• Nanoarchitectures for Neglected Tropical Protozoal Diseases: Challenges and State of the Art

  2017cites this paper
• Nanostructures for Improved Antimonial Therapy of Leishmaniasis

  2017cites this paper
• Nanotechnological Strategies for Treatment of Leishmaniasis--A Review.

  2017cites this paper
• Nerolidol, the main constituent of Piper aduncum essential oil, has anti-Leishmania braziliensis activity

  2017cites this paper
• MACROPHAGE TARGETING: A STRATEGY FOR LEISHMANIASIS SPECIFIC DELIVERY

  2016cites this paper
• Coating doxorubicin‐loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1‐type immune responses

  2014cites this paper
• Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis

  2014cites this paper
• In vitro biological evaluation of eight different essential oils against Trypanosoma cruzi, with emphasis on Cinnamomum verum essential oil

  2014cites this paper
• Targeting strategies for delivery of anti-HIV drugs

  2014cites this paper
• donovani Leishmania Established and Chronic Stearylamine-Bearing Liposomes against Antimony Gluconate in Combination Therapy Using Sodium

  2014cites this paper
• Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis.

  2014cites this paper
• In Vitro Antileishmanial Activity of Essential Oil of Vanillosmopsis arborea (Asteraceae) Baker

  2013cites this paper
• Over-Expression of 60s Ribosomal L23a Is Associated with Cellular Proliferation in SAG Resistant Clinical Isolates of Leishmania donovani

  2013cites this paper
• Innovative lead compounds and formulation strategies as newer kinetoplastid therapies.

  2012cites this paper
• In vitro phototoxicity of ultradeformable liposomes containing chloroaluminum phthalocyanine against New World Leishmania species.

  2012cites this paper
• Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis.

  2012cites this paper
• Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis

  2012cites this paper
• Characterization of Ace-Liposome Receptor-mediated Endocytic Pathways in Leishmania Infected J774 Cells: Effect of Lysosomotropic Agents and Inhibitors of Oxidative Phosphorylation*

  2012cites this paper
• Intracellular Bacteria and Protozoa

  2011cites this paper
• Mannosylated liposomes bearing Amphotericin B for effective management of visceral Leishmaniasis

  2011cites this paper
• Antileishmanial Drugs: search for t SIR2 inhibitors

  2011cites this paper
• New delivery strategies for the old pentavalent antimonial drugs

  2010cites this paper
• Emerging role of vesicular carriers for therapy of visceral leishmaniasis: conventional versus novel.

  2010cites this paper
• Immunomodulators: Potential in Treatment of Systemic Fungal Infections

  2010cites this paper
• Drug delivery strategies for therapy of visceral leishmaniasis

  2010cites this paper
• Accumulation of Drugs in Tissues

  2010cites this paper
• Leishmania amazonensis Growth Inhibitors: Biological and Theoretical Features of Sulfonamide 4-Methoxychalcone Derivatives

  2009cites this paper
• In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis

  2009cites this paper
• State of the Art of Nanobiotechnology Applications in Neglected Diseases

  2009cites this paper
• Development of Amphotericin B Loaded PLGA Nanoparticles for Effective Treatment of Visceral Leishmaniasis

  2009cites this paper
• Preparation, Characterization and Evaluation of Targeting Potential of Amphotericin B-Loaded Engineered PLGA Nanoparticles

  2009cites this paper
• DELIVERY SYSTEMS FOR THE TREATMENT AND PREVENTION OF LEISHMANIASIS

  2009cites this paper
• Drug delivery systems against leishmaniasis? Still an open question.

  2008cites this paper
• Drug delivery systems against leishmaniasis? Still an open question

  2008cites this paper
• Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis

  2007cites this paper
• Antileishmanial potential of a marine sponge, Haliclona exigua (Kirkpatrick) against experimental visceral leishmaniasis

  2007cites this paper
• Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles.

  2007cites this paper
• In vitro and in vivo leishmanicidal activity of Dysoxylum binectariferum and its fractions against Leishmania donovani.

  2007cites this paper
• Targeting of antileishmanial drugs produced by nanotechnologies

  2007cites this paper
• Immunomodulatory properties of new conjugates of muramyl dipeptide and nor-muramyl dipeptide with retro-tuftsin (Arg-Pro-Lys-Thr-OMe).

  2006cites this paper
• Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections.

  2005influential citation
• Liposomal Delivery of Antileishmanial Agents

  2005cites this paper
• Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice.

  2004cites this paper
• Anti-Leishmanial Drug Delivery: Acetylated LDL as A Site-Specific Delivery Ligand

  2004cites this paper
• Combination Therapy Using Sodium Antimony Gluconate in Stearylamine-Bearing Liposomes against Established and Chronic Leishmania donovani Infection in BALB/c Mice

  2004cites this paper
• Macrophage specific drug delivery in experimental leishmaniasis.

  2004cites this paper
• Prophylactic Role of Immunomodulators in Treatment of Systemic Candidiasis in Leukopenic Mice

  2004cites this paper
• Antileishmanial action of Tephrosia purpurea linn, extract and its fractions against experimental visceral leishmaniasis

  2003cites this paper
• Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs

  2003cites this paper
• Use of Tuftsin Bearing Nystatin Liposomes against an Isolate of Candida albicans showing Less In Vivo Susceptibility to Amphotericin B

  2003cites this paper
• Superior Chemotherapeutic Efficacy of Amphotericin B in Tuftsin-bearing Liposomes against Leishmania Donovani Infection in Hamsters

  2002cites this paper
• Immunomodulatory potential of hydrophobic analogs of Rigin and their role in providing protection against Plasmodium berghei infection in mice.

  2001cites this paper
• Enhanced Immunostimulant Activity and Protective Effect of a Synthetic Lipopeptide after Liposomization Against Plasmodium berghei Infection in Mice

  2001cites this paper
• Endogenous carriers and ligands in non-immunogenic site-specific drug delivery.

  2000cites this paper
• Tuftsin-bearing liposomes in treatment of macrophage-based infections.

  2000cites this paper
• Activity of the Novel Immunomodulatory Compound Tucaresol against Experimental Visceral Leishmaniasis

  2000cites this paper
• Antibody-bearing liposomes as chloroquine vehicles in treatment of murine malaria.

  2000cites this paper
• Tuftsin: on the 30-year anniversary of Victor Najjar's discovery.

  1999cites this paper
• In vitro study of the anti-leishmanial activity of biodegradable nanoparticles.

  1995cites this paper
• Liposomes in drug targeting.

  1994cites this paper
• Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice

  1994cites this paper
• Tuftsin‐bearing liposomes as drug vehicles in the treatment of experimental aspergillosis

  1993cites this paper
• Antileishmanial Activity of Traditional Plants against Leishmania donovani in Golden Hamsters

  1992cites this paper
• Serum opsonins and liposomes: their interaction and opsonophagocytosis.

  1992cites this paper
• Respiratory burst in peritoneal exudate cells in response to a modified tuftsin

  1992cites this paper
• Kala‐Azar: Current status of experimental chemotherapy

  1992cites this paper
• Iridoids: a new class of leishmanicidal agents from Nyctanthes arbortristis.

  1991cites this paper
• Rifampin Vehicles in Treatment of Tuberculosis in Micet

  year unknowncites this paper